Trial Profile
An Open Label Extension Study to Evaluate the Safety, Tolerability and Pharmacokinetics of STX209 in Subjects With Fragile X Syndrome
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 31 Oct 2014
Price :
$35
*
At a glance
- Drugs Arbaclofen (Primary)
- Indications Fragile X syndrome
- Focus Therapeutic Use
- Sponsors Seaside Therapeutics
- 31 Oct 2014 New trial record